Skip to main content
Log in

Human tissue distribution of 4′-(9-acridinylamino)-methanesulfon-m-anisidide (NSC 141549, AMSA)

  • Original Articles
  • AMSA, Tissue Distribution
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Concentrations of AMSA were determined by HPLC in autopsy tissue samples from five patients who had received the drug antemortem. Relative organ concentrations of AMSA varied from patient to patient; however, concentrations were generally highest in gallbladder, liver, and kidney, while low levels were generally but not invariably found in lung, testicle, muscle, fat, spleen, bladder, pancreas, colon, prostate, and brain. One patient with ventricular fibrillation and seizures had high tissue AMSA concentrations in myocardium, but low concentrations in brain. Another patient with seizures during treatment had high brain concentrations of AMSA. Relative organ concentrations were similar to those found in mice, except that mice have high AMSA concentration in their spleens whereas our patients did not, even when the spleen was infiltrated with leukemic cells. High tissue concentrations of AMSA were still present 2 weeks after treatment. AMSA concentration was lower in a renal oncocytoma (1.1 μg/g) than in surrounding kidney (2.4 μg/g).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Abbreviations

AMSA:

4′-(9-acridinylamino)-methanesulfon-m-anisidide

HPLC:

high-performance liquid chromatography

AML:

acute myelogenous leukemia

LLD:

lower limit of detection

References

  1. Cabanillas F, Legha S, Bodey G, Freireich E (1981) Initial experience with AMSA as single-agent treatment against malignant lymphoproliferative disorders. Blood 57:614–616

    Google Scholar 

  2. Cysyk R, Shoemaker D, Adamson R (1977) The pharmacologic disposition of 4′-(9-acridinylamine)methanesulfon-m-anisidide in mice and rats. Drug Metab Dispos 5:579–589

    Google Scholar 

  3. Dorn RT, Fritz WL (1980) Cancer chemotherapy handbook. Elsevier/North Holland, New York

    Google Scholar 

  4. Drewinko B, Yang L, Barlogie B (1982) Lethal activity and kinetic response of cultured human cells to 4′-(9-acridinylamino)methanesulfon-m-anisidide. Cancer Res 42:107–111

    Google Scholar 

  5. El Dareen SJ, Mulligan LT Jr, White V, Tillery K, Mellett LB, Hill DL (1978) Distribution of (3H) cytosine arabinoside and its products in mice, dogs, and monkeys and effects of tetrahydrouridine. Cancer Treat Rep 61:395–407

    Google Scholar 

  6. Falkson G (1979) Multiple ventricular extrasystoles following administration of 4′-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) Cancer Treat Rep 63:358

    Google Scholar 

  7. Houghton A, Camacho F, Wittes R, Young C (1981) Phase II study of AMSA in patients with metastatic malignant melanoma. Cancer Treat Rep 65:170–171

    Google Scholar 

  8. Legha S, Gutterman J, Hall S, Benjamin R, Burgess M, Valdivieso M, Bodey G (1978) Phase I clinical investigation of 4′-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992), a new acridine derivative. Cancer Res 38:3712–3716

    Google Scholar 

  9. Legha S, Blumenschein G, Buzdar A, Hortobagyi G, Bodey G (1979a) Phase II study of 4′-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in metastatic breast cancer. Cancer Treat Rep 63:1961–1964

    Google Scholar 

  10. Legha S, latreille J, McCredie K, Bodey G (1979b) Neurologic and cardiac rhythm abnormalities associated with 4′-(9-acridinylamino)methane-m-anisidide (AMSA) therapy. Cancer Treat Rep 63:2001–2003

    Google Scholar 

  11. Legha S, Keating M, Zander A, McCredie K, Freireich E (1980) 4′-(9-Acridinylamino)methanesulfon-m-anisidide (AMSA): A new drug effective in the treatment of adult acute leukemia. Ann Intern Med 93:17–21

    Google Scholar 

  12. Nichols W, Eagan R, Frytak S, Ingle J, Creagan J, Kvols L (1980) Phase II evaluation of AMSA in patients with metastic lung cancer. Cancer Treat Rep 64:1383–1385

    Google Scholar 

  13. Salmon SE, Hamburger AW, Solhnlen BJ, Durie BGM, Alberts DS, Moon TE (1978) Quantitation of differential sensitivity of human tumor stem cells to anticancer drugs. N Engl J Med 298:1321–1322

    Google Scholar 

  14. Shoemaker D, Legha S, Cysyk R (1978) Selective localization of 4′-(9-acridinylamino)methanesulfon-m-anisidide in B16 melanoma. Pharmacology 16:221–225

    Google Scholar 

  15. Sordillo P, Magill G, Gralla R, Golbey R (1980) Phase II evaluation of 4′-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with advanced sarcoma. Cancer Treat Rep 64:1129–1130

    Google Scholar 

  16. Von Hoff D, Howser D, Gormely P, Bender R, Glaubiger D, Levine A, Young R (1978) Phase I study of methanesulfonamide, N-(4-(9-acridinylamino)-3-methoxphenyl)-m (m-AMSA) using a single-dose schedule. Cancer Treat Rep 62:1421–1426

    Google Scholar 

  17. Von Hoff D, Elson D, Polk G, Coltman C Jr (1980) Acute ventricular fibrillation and death during infusion of 4′-(9-acridinylamino)methane-m-anisidide (AMSA). Cancer Treat Rep 64:356–357

    Google Scholar 

  18. Zhengang G, Stewart D, Lu K, Savaraj N, Leavens M, Feun L, Benjamin R, Loo TL (1982) Tumor penetration of AMSA in man. Proc Am Soc Clin Oncol 1:17

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stewart, D.J., Zhengang, G., Lu, K. et al. Human tissue distribution of 4′-(9-acridinylamino)-methanesulfon-m-anisidide (NSC 141549, AMSA). Cancer Chemother. Pharmacol. 12, 116–119 (1984). https://doi.org/10.1007/BF00254602

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00254602

Keywords

Navigation